The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data.

ABSTRACT:

Background

Biosimilars have the potential to save a significant amount of money in cancer treatment costs. However, barriers exist in the adoption of biosimilar products. Japan introduced a new health policy in 2022 to promote the use of biosimilars in oncology by offering financial incentives to eligible hospitals. This study aims to examine the association between these financial incentives and prescription patterns.

Methods

The study analyzed Diagnosis Procedure Combination (DPC) data to assess the impact of the new health policy on the use of biosimilar products in oncology. The policy provided an additional fee for hospitals using biosimilar products. The study included patients with specific types of cancer and analyzed the proportion of monthly biosimilar prescription

SUBMITTER: Itoshima H 

PROVIDER: S-EPMC11563361 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature